Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04150289 · ClinicalTrials.gov registry record
A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat
A clinical trial, sponsored by pharmaand.
- Completed
- Registry status
- 248
- Enrollment target
NCT04150289: Completed study, sponsored by pharmaand.
NCT04150289 is a clinical trial that has completed, run by pharmaand. The registered enrollment target is 248 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04150289 has completed, sponsored by pharmaand.
- COMPLETED
- Registry status
- 248 participants
- Enrollment target
Study Summary
This study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes.
Primary Outcome
Looking for patient reproted response to treatment with panobinostat
Interventions
- DRUG Farydak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2019-11-04 |
| Est. Completion | 2022-03-30 |
What the finished NCT04150289 record still lists
NCT04150289 is an observational study that tracks outcomes without assigning an intervention. The registered 248 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Farydak is the first listed.
NCT04150289 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04150289 about?
NCT04150289 is a clinical study titled "A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat". This study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with baseline patient characteristics, healthcare resource utilization, and cli...
What is the current status of trial NCT04150289?
This trial is currently completed. The enrollment target is 248 participants. The study started on 2019-11-04. Estimated completion is 2022-03-30.
What interventions are being tested in trial NCT04150289?
The interventions under investigation include: Farydak (DRUG).
Who is sponsoring clinical trial NCT04150289?
This trial is sponsored by pharmaand, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04577911 · 248 participants
How is Social Connection Represented in the Brain?
- NCT04777994 · 248 participants · Phase 1
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- NCT04792489 · 248 participants · Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
- NCT04830137 · 248 participants · Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI